- Home
- QQQX vs COGT Comparison
QQQX vs COGT Comparison
Compare QQQX & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QQQX
- COGT
- Stock Information
- Founded
- QQQX 2007
- COGT 2014
- Country
- QQQX United States
- COGT United States
- Employees
- QQQX N/A
- COGT N/A
- Industry
- QQQX Finance Companies
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- QQQX Finance
- COGT Health Care
- Exchange
- QQQX Nasdaq
- COGT Nasdaq
- Market Cap
- QQQX 1.2B
- COGT 984.0M
- IPO Year
- QQQX N/A
- COGT 2018
- Fundamental
- Price
- QQQX $25.76
- COGT $8.98
- Analyst Decision
- QQQX
- COGT Buy
- Analyst Count
- QQQX 0
- COGT 6
- Target Price
- QQQX N/A
- COGT $14.67
- AVG Volume (30 Days)
- QQQX 127.6K
- COGT 1.5M
- Earning Date
- QQQX 01-01-0001
- COGT 11-12-2024
- Dividend Yield
- QQQX 7.03%
- COGT N/A
- EPS Growth
- QQQX N/A
- COGT N/A
- EPS
- QQQX N/A
- COGT N/A
- Revenue
- QQQX N/A
- COGT N/A
- Revenue This Year
- QQQX N/A
- COGT N/A
- Revenue Next Year
- QQQX N/A
- COGT N/A
- P/E Ratio
- QQQX N/A
- COGT N/A
- Revenue Growth
- QQQX N/A
- COGT N/A
- 52 Week Low
- QQQX $20.27
- COGT $3.67
- 52 Week High
- QQQX $25.99
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- QQQX 52.47
- COGT 31.03
- Support Level
- QQQX $25.60
- COGT $8.56
- Resistance Level
- QQQX $26.33
- COGT $9.30
- Average True Range (ATR)
- QQQX 0.28
- COGT 0.73
- MACD
- QQQX -0.04
- COGT -0.20
- Stochastic Oscillator
- QQQX 59.86
- COGT 11.54
About QQQX Nuveen NASDAQ 100 Dynamic Overwrite Fund Shares of Beneficial Interest
Nuveen NASDAQ 100 Dynamic Overwrite Fund is a closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Nasdaq 100 Index. Under normal circumstances, the Fund will invest at least 80% of its Assets in an equity portfolio made up of securities comprising the Nasdaq 100 Index (or securities that have economic characteristics that are similar to those securities comprising the Nasdaq 100 Index) that seeks to substantially replicate price movements of the Nasdaq 100 Index and is designed to support the Fund's option strategy.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.